vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $18.6M, roughly 1.0× Zeo Energy Corp.). Zeo Energy Corp. runs the higher net margin — -10.8% vs -90.7%, a 79.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -0.4%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMS vs ZEO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $18.6M |
| Net Profit | $-17.4M | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | -11.8% |
| Net Margin | -90.7% | -10.8% |
| Revenue YoY | 740.1% | -0.4% |
| Net Profit YoY | 55.5% | -360.9% |
| EPS (diluted) | $-0.15 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | $19.1M | $18.1M | ||
| Q1 25 | — | $8.8M | ||
| Q4 24 | $12.8M | $18.6M | ||
| Q3 24 | $29.1M | $19.7M | ||
| Q2 24 | — | $14.8M | ||
| Q1 24 | — | $20.1M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | $-17.4M | $-2.4M | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | $-92.2M | $-435.3K | ||
| Q3 24 | $-16.6M | $-424.3K | ||
| Q2 24 | — | $-277.8K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | -11.8% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | -186.1% | -15.8% | ||
| Q1 25 | — | -153.8% | ||
| Q4 24 | -338.5% | -6.0% | ||
| Q3 24 | -85.9% | -15.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | -20.1% |
| Q4 25 | — | -10.8% | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | -90.7% | -13.3% | ||
| Q1 25 | — | -72.4% | ||
| Q4 24 | -721.7% | -2.3% | ||
| Q3 24 | -57.2% | -2.2% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -7.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | $-0.91 | $1.11 | ||
| Q3 24 | $-0.18 | $-0.08 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $778.5M | $5.3M |
| Total Assets | $815.1M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $739.2M | $68.7K | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $834.2M | $5.6M | ||
| Q3 24 | $422.7M | $4.3M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $778.5M | $-59.4M | ||
| Q1 25 | — | $-23.1M | ||
| Q4 24 | $757.5M | $-88.9M | ||
| Q3 24 | $378.9M | $-39.3M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-173.0M |
| Q4 25 | — | $56.9M | ||
| Q3 25 | — | $58.5M | ||
| Q2 25 | $815.1M | $46.2M | ||
| Q1 25 | — | $47.4M | ||
| Q4 24 | $864.6M | $61.0M | ||
| Q3 24 | $439.2M | $47.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $2.4M |
| Free Cash FlowOCF − Capex | $-37.8M | $2.3M |
| FCF MarginFCF / Revenue | -197.2% | 12.2% |
| Capex IntensityCapex / Revenue | 0.5% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-6.6M | ||
| Q2 25 | $-37.7M | $-2.3M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | $-37.5M | $3.5M | ||
| Q3 24 | $-12.5M | $162.2K | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | — | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | $-37.8M | $-2.7M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | $-37.5M | $3.4M | ||
| Q3 24 | $-12.6M | $116.5K | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | -197.2% | -15.0% | ||
| Q1 25 | — | -30.0% | ||
| Q4 24 | -293.5% | 18.2% | ||
| Q3 24 | -43.2% | 0.6% | ||
| Q2 24 | — | -15.6% | ||
| Q1 24 | — | -51.5% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 0.5% | 2.4% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
